The first phase of clinical trials of the first Iranian mRNA vaccine Renap against COVID-19 has started in Iran. The drug was administered to a male volunteer on February 25, according to the Iranian news agency IRNA.
The procedure took place at Imam Khomeini Hospital, a teaching hospital complex and biomedical research center of the Tehran University of Medical Sciences, in the presence of officials, representatives of the academic community and the drug development company.
Iran’s Food and Drug Administration issued permission for clinical trials of the drug.
The drug “Renap” was developed by the science-intensive Danish company Banyan Renap. It is reported that the company was able to locate in Iran the technology for the production of mRNA-based vaccines, which was first used by the US companies Pfizer and Moderna.
Recall that in the US Senate on December 7, 2022, in the third round on the problems of vaccination against coronaviruses, one of the authors of the idea of mRNA vaccines, Dr. gene therapy .
Johnson & Johnson pharmacologist David Wiseman told the roundtable that the FDA’s “gene therapy” standards are stricter than those for vaccines, and include 5 to 15 years of follow-up for possible oncology occurrence. experimental, autoimmune and neurological diseases and DNA damage. At the same time, when evaluating the safety of mRNA vaccines, the FDA, for some reason, decided to follow the standards for vaccines, even though the drug falls under the concept of “gene therapy,” he added.
US Army Medical Corps Lt. Col. Teresa Long told the Senate that “The risks of vaccines outweigh the benefits”noted that the number of servicemen who died after vaccination exceeded the number of coronavirus deaths, and called for an end to mandatory vaccination in the military.
Also read: Why were COVID vaccines needed?
Also read: Overview of the US Senate Hearings on mRNA Vaccines
Source: Rossa Primavera
I am Michael Melvin, an experienced news writer with a passion for uncovering stories and bringing them to the public. I have been working in the news industry for over five years now, and my work has been published on multiple websites. As an author at 24 News Reporters, I cover world section of current events stories that are both informative and captivating to read.